Alitretinoin: profile and news

(PZ) Basilea Pharmaceutica Ltd. Reports 2005 Financial Results Feb 27, 2006
...announced positive phase II trial results on our novel broad-spectrum antifungal drug BAL8557 and our international phase III alitretinoin registration trial ... - Houston Chronicle,

Basilea announces positive phase III results for ceftobiprole, its ... Mar 2, 2006
About Alitretinoin (BAL4079) Alitretinoin is a novel vitamin A analog that is developed for patients with chronic hand eczema that is refractory to ... - PharmaLive.com (press release),

Basilea Pharmaceutica Ltd. Reports its Interim Results Aug 23, 2005
The increase in R&D spending resulted primarily from progress in late stage development of Alitretinoin (BAL4079) for the treatment of chronic refractory hand ... - PrimeZone (press release),

Ordinary General Meeting of Shareholders of Basilea Pharmaceutica ... Apr 12, 2005
BAL5788) into phase III in complicated skin and skin structure infections and hospital acquired pneumonia; the entry of alitretinoin (BAL4079) for severe ... - ArriveNet

Basilea's First-in-Class Antibiotic BAL5788 (Ceftobiprole) Moves ... Apr 7, 2005
...including the entry of ceftobiprole (BAL5788) into phase III in complicated skin and skin structure infections; the entry of alitretinoin (BAL4079) for severe ... - ArriveNet,

Basilea Announces 2004 Financial Results Reflecting Successful ... Mar 9, 2005
Basilea commenced its alitretinoin phase III program in severe chronic hand dermatitis refractory to topical treatment -- October 2004. ... - PrimeZone (press release),

Basilea Investigates Novel Antibiotic Class with Potential to ... Mar 7, 2005
...months, Basilea also announced three additional major company milestones including entry of ceftobiprole into phase III, entry of alitretinoin (BAL4079) in ... - PrimeZone (press release),

Other information

Indication
For topical treatment of cutaneous lesions in patients with AIDS- related Kaposi sarcomaia.

Pharmacology
Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS- related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro.

Mechanism Of Action
Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells.

Drug Category
Antineoplastic Agents; ATC:L01XX22

Brand Names/Synonyms
Alitretinoin; Alitretinoin [Usan]; Avita; Beta-Retinoic Acid; Panretin; Panretin Gel; Panretyn; Panrexin; Renova; Retin-A; Retin-a Micro; Retinoate; Retinoic Acid; Trans-Retinoic Acid; Tretin M; Tretinoin; Vesanoid; Vitamin a Acid

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Interactions for Alitretinoin:

Patients who are applying Panretin® gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products. Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation. Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin® gel on the steady-state concentrations of these drugs is not known. No drug interaction data are available on concomitant administration of Panretin® gel and systemic anti-KS agents.

Chemical IUPAC Name
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoicacid

Chemical Formula
C20H28O2

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
APRD00017

CAS Registry Number
3/8/5300